Loading
A phase 3 trial of Iruplinalkib and Crizotinib in Non-small-cell lung cancer, run by Qilu Pharmaceutical Co., Ltd., with a status the registry has not verified recently.
Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients is a phase 3 interventional study registered as NCT04632758 by Qilu Pharmaceutical Co., Ltd., with 292 participants planned, started 2019-06-01 and due to reach its primary completion in 2024-12-01. Interventions recorded: WX-0593 Tablets, crizotinib. Conditions recorded: Non-small Cell Lung Cancer.
Linked to the drug Iruplinalkib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Iruplinalkib, Qilu Pharmaceutical, ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Iruplinalkib, ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Crizotinib, Non-small-cell lung cancer and the tag pipeline.
Shares Crizotinib, Non-small-cell lung cancer and the tag pipeline.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.